codeine phosphate; phenylephrine hydrochloride; promethazine hydrochloride
Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
Phenergan VC with Codeine is a combination oral syrup containing codeine phosphate (opioid antitussive), phenylephrine hydrochloride (nasal decongestant), and promethazine hydrochloride (antihistamine/anticholinergic). It is indicated for symptomatic relief of cough and upper respiratory congestion associated with allergies or the common cold. The formulation works through multiple mechanisms: codeine suppresses cough reflex, phenylephrine reduces nasal congestion via sympathomimetic action, and promethazine provides antihistamine and sedating effects.
This legacy product faces declining market dynamics with moderate competitive pressure (30/100), signaling a smaller, maintenance-focused team focused on market defense rather than growth.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on Phenergan VC with Codeine offers limited career growth and mobility due to its late-lifecycle stage and minimal linked job activity. Roles focus on defending market share, managing generic competition, and regulatory compliance rather than innovation or expansion.
Worked on PHENERGAN VC W/ CODEINE at ANI Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.